Originally Published as The Niche Podcast

Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D.



Sponsors
https://www.thescopemethod.com


Story References
https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
https://www.abcellera.com/news/2020-12-10-abcellera-announces-pricing-of-ipo
https://www.certara.com/pressrelease/certara-announces-pricing-of-its-upsized-initial-public-offering/
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-upsized-pricing-initial
https://www.nanobiotix.com/wp-content/uploads/2020/12/PR-Pricing.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-sciences-to-acquire-myr-gmbh


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

 
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Everlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA.


Sponsors

https://www.thescopemethod.com


Story References

https://www.prnewswire.com/news-releases/everlywell-announces-175-million-financing-to-expand-consumer-lab-testing-and-digital-health-offerings-301185355.html

https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T?Open&parent=news-overview-category-search-en&ccm=020

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study


Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This week, we take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal experience being hospitalized with COVID19.

Sponsors
https://www.thescopemethod.com

Trenton's Website
https://www.nmtworks.com/

Aphasia Choir
https://singaphasia.com/

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million



Story References
https://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/
https://www.biospace.com/article/releases/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering/
https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy

 
Sponsors
https://www.thescopemethod.com

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

COVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public.



Sponsors
https://www.thescopemethod.com

Story References
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
https://night-ware.com/news
https://investor.agios.com/news-releases/news-release-details/agios-announces-fda-orphan-drug-designation-granted-mitapivat-0
https://sec.report/Document/0001193125-20-290236/


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.


Sponsors
https://www.thescopemethod.com

Story References
https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers
https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Syneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.



Sponsors
https://www.thescopemethod.com

Story References
https://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-acquire-synteract-top-cro-provider-emerging
https://www.prnewswire.com/news-releases/new-greenphire-data-indicates-clinical-trial-industrys-swift-rebound-patient-enrollment-reaches-pre-pandemic-levels-301159557.html?tc=eml_cleartime
https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-enter-collaboration-global-co-development-and
 

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.




Sponsors

https://www.thescopemethod.com

Story References

https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-the-Clinical-Trial-Experience-And-Streamlines-the-Drug-Development-Process

https://www.businesswire.com/news/home/20201020005345/en/IQVIA-Reports-Third-Quarter-2020-Results-Raises-Full-Year-2020-Guidance-and-Provides-2021-Outlook

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-third-quarter-2020-results-301156312.html

https://www.bmj.com/content/371/bmj.m3939

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
 

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.



Sponsors

https://www.thescopemethod.com

Story References

https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-study-results-patients

https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-positive-data-iw-6463-cns-translational

https://novotech-cro.com/news/asia-pacific-has-record-year-clinical-trials-according-novotech 

https://investors.praxismedicines.com/press-releases

https://www.pnas.org/content/early/2020/10/07/2012379117

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Nobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political



Sponsors
https://www.thescopemethod.com

Story References
https://www.nobelprize.org/prizes/chemistry/2020/summary/
https://stm.sciencemag.org/content/12/564/eabb2830
https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html
https://www.businesswire.com/news/home/20201008005340/en/

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.